APEN Stock Overview
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices.
Apollo Endosurgery Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.65|
|52 Week High||US$10.39|
|52 Week Low||US$3.51|
|1 Month Change||-14.32%|
|3 Month Change||-38.96%|
|1 Year Change||-55.70%|
|3 Year Change||15.14%|
|5 Year Change||-50.48%|
|Change since IPO||-69.98%|
Recent News & Updates
|APEN||US Medical Equipment||US Market|
Return vs Industry: APEN underperformed the US Medical Equipment industry which returned -25.9% over the past year.
Return vs Market: APEN underperformed the US Market which returned -21.7% over the past year.
|APEN Average Weekly Movement||9.0%|
|Medical Equipment Industry Average Movement||10.5%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: APEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: APEN's weekly volatility (9%) has been stable over the past year.
About the Company
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands.
Apollo Endosurgery Fundamentals Summary
|APEN fundamental statistics|
Is APEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|APEN income statement (TTM)|
|Cost of Revenue||US$28.97m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.71|
|Net Profit Margin||-43.31%|
How did APEN perform over the long term?See historical performance and comparison
Is APEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for APEN?
Other financial metrics that can be useful for relative valuation.
|What is APEN's n/a Ratio?|
Price to Sales Ratio vs Peers
How does APEN's PS Ratio compare to its peers?
|APEN PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
TCMD Tactile Systems Technology
APEN Apollo Endosurgery
Price-To-Sales vs Peers: APEN is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (16.9x).
Price to Earnings Ratio vs Industry
How does APEN's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: APEN is good value based on its Price-To-Sales Ratio (2.2x) compared to the US Medical Equipment industry average (3.7x)
Price to Sales Ratio vs Fair Ratio
What is APEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.2x|
|Fair PS Ratio||3.8x|
Price-To-Sales vs Fair Ratio: APEN is good value based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (3.8x).
Share Price vs Fair Value
What is the Fair Price of APEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate APEN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate APEN's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APEN's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Apollo Endosurgery forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APEN's revenue (25% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: APEN's revenue (25% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APEN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Apollo Endosurgery performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APEN is currently unprofitable.
Growing Profit Margin: APEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APEN is unprofitable, but has reduced losses over the past 5 years at a rate of 10.9% per year.
Accelerating Growth: Unable to compare APEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: APEN has a negative Return on Equity (-51.78%), as it is currently unprofitable.
Discover strong past performing companies
How is Apollo Endosurgery's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: APEN's short term assets ($108.5M) exceed its short term liabilities ($14.0M).
Long Term Liabilities: APEN's short term assets ($108.5M) exceed its long term liabilities ($56.0M).
Debt to Equity History and Analysis
Debt Level: APEN has more cash than its total debt.
Reducing Debt: APEN's debt to equity ratio has increased from 95.6% to 96.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APEN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: APEN has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 4.4% each year.
Discover healthy companies
What is Apollo Endosurgery current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as APEN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chas McKhann (53 yo)
Mr. Charles S. McKhann, also known as Chas, serves as President, Chief Executive Officer and Director at Apollo Endosurgery, Inc since March 01, 2021. He served as Chief Commercial Officer at Torax Medical...
CEO Compensation Analysis
Compensation vs Market: Chas's total compensation ($USD8.66M) is above average for companies of similar size in the US market ($USD765.69K).
Compensation vs Earnings: Insufficient data to compare Chas's compensation with company performance.
Experienced Management: APEN's management team is considered experienced (3.5 years average tenure).
Experienced Board: APEN's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.9%.
Apollo Endosurgery, Inc.'s employee growth, exchange listings and data sources
- Name: Apollo Endosurgery, Inc.
- Ticker: APEN
- Exchange: NasdaqGM
- Founded: 2005
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$146.914m
- Shares outstanding: 40.25m
- Website: https://www.apolloendo.com
Number of Employees
- Apollo Endosurgery, Inc.
- Building 1
- Suite 300
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/01 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.